Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 166 Records) |
| Query Trace: Diarrhea and EGFR[original query] |
|---|
| Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of oncology 2021 12 2021 8736288. Zhang Lemeng, Luo Yongzhong, Chen Jianhua, Cheng Tianli, Yang Hua, Pan Changqie, Li Haitao, Jiang Zh |
| RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug safety 2021 12 45 (1): 45-64. Nadal Ernest, Horinouchi Hidehito, Shih Jin-Yuan, Nakagawa Kazuhiko, Reck Martin, Garon Edward B, Wei Yu-Feng, Kollmeier Jens, Frimodt-Moller Bente, Barrett Emily, Lipkovich Olga, Visseren-Grul Carla, Novello Silv |
| A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer management and research 2021 12 13 8695-8705. Igawa Satoshi, Kasajima Masashi, Ono Taihei, Ozawa Takahiro, Kakegawa Mikiko, Kusuhara Seiichiro, Sato Takashi, Nakahara Yoshiro, Fukui Tomoya, Yokoba Masanori, Kubota Masaru, Mitsufuji Hisashi, Sasaki Jiichiro, Naoki Katsuhi |
| First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational new drugs 2021 11 40 (2): 430-437. Igawa Satoshi, Fukui Tomoya, Kasajima Masashi, Ono Taihei, Ozawa Takahiro, Kakegawa Mikiko, Kusuhara Seiichiro, Sato Takashi, Nakahara Yoshiro, Hisashi Mitsufuji, Sasaki Jiichiro, Naoki Katsuhi |
| A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
| FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
| Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic advances in medical oncology 2022 7 14 17588359221113278. Lee Suey-Haur, Lin Yu-Ching, Chiu Li-Chung, Ju Jia-Shiuan, Tung Pi-Hung, Huang Allen Chung-Cheng, Li Shih-Hong, Fang Yueh-Fu, Chen Chih-Hung, Kuo Scott Chih-Hsi, Wang Chin-Chou, Yang Cheng-Ta, Hsu Ping-Ch |
| Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study. Journal of thoracic disease 2022 Jun 14 (6): 2169-2177. Qian Jie, Ye Xuanting, Huang Aimi, Qin Ruoyan, Cai Yuqing, Xue Yiqian, Zhang Shi, Wang Weimin, Xiong Liwen, Gu Aiq |
| Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Jun OF1-OF10. Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
| Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 5 . Yang James Chih-Hsin, Ohe Yuichiro, Chiu Chao-Hua, Ou Xiaoling, Cantarini Mireille, Jänne Pasi A, Hartmaier Ryan J, Ahn Myung |
| AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 5 40 (27): 3162-3171. Lu Shun, Dong Xiaorong, Jian Hong, Chen Jianhua, Chen Gongyan, Sun Yuping, Ji Yinghua, Wang Ziping, Shi Jianhua, Lu Junguo, Chen Shaoshui, Lv Dongqing, Zhang Guojun, Liu Chunling, Li Juan, Yu Xinmin, Lin Zhong, Yu Zhuang, Wang Zhehai, Cui Jiuwei, Xu Xingxiang, Fang Jian, Feng Jifeng, Xu Zhi, Ma Rui, Hu Jie, Yang Nong, Zhou Xiangdong, Wu Xiaohong, Hu Chengping, Zhang Zhihong, Lu You, Hu Yanping, Jiang Liyan, Wang Qiming, Guo Renhua, Zhou Jianying, Li Baolan, Hu Chunhong, Tong Wancheng, Zhang Helong, Ma Lin, Chen Yuan, Jie Zhijun, Yao Yu, Zhang Longzhen, Jie Weng, Li Weidong, Xiong Jianping, Ye Xianwei, Duan Jianchun, Yang Haihua, Sun Meili, Sun Changan, Wei Hongying, Li Chuan, Ali Siraj M, Miller Vincent A, Wu Qio |
| Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung cancer (Amsterdam, Netherlands) 2022 4 168 38-45. Hayashi Hidetoshi, Yonesaka Kimio, Nakamura Atsushi, Fujimoto Daichi, Azuma Koichi, Sakata Shinya, Tachihara Motoko, Ikeda Satoshi, Yokoyama Toshihide, Hataji Osamu, Yano Yukihiro, Hirano Katsuya, Daga Haruko, Okada Hideaki, Chiba Yasutaka, Sakai Kazuko, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thoracic cancer 2022 4 13 (10): 1471-1478. Tanaka Hisashi, Sakamoto Hiroaki, Akita Takahiro, Ohyanagi Fumiyoshi, Kawashima Yosuke, Tambo Yuichi, Tanimoto Azusa, Horiike Atsushi, Miyauchi Eisaku, Tsuchiya-Kawano Yuko, Yanagitani Noriko, Nishio Mako |
| A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung cancer (Amsterdam, Netherlands) 2022 3 166 98-106. Lin Lin, Pan Hongming, Li Xingya, Zhao Chengling, Sun Jiangtao, Hu Xingsheng, Zhang Yiping, Wang Mengzhao, Ren Xiubao, Luo Xiaoyong, Shan Guoyong, Hui Ai-Min, Wu Zhuli, Liu Huilong, Tian Ling, Shi Yuank |
| Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC cancer 2022 3 22 (1): 328. Zhao Pengfei, Zhen Hongchao, Zhao Hong, Zhao Lei, Cao Bangw |
| Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC medicine 2022 Feb 20 (1): 42. Song Zhengbo, Li Yuping, Chen Shiqing, Ying Shenpeng, Xu Shuguang, Huang Jianjin, Wu Dan, Lv Dongqing, Bei Ting, Liu Shuxun, Huang Xiaoping, Xie Congying, Wu Xiaoyu, Fu Jianfei, Hua Feng, Wang Wenxian, Xu Chunwei, Gao Chan, Cai Shangli, Lu Shun, Zhang Yipi |
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353. Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J |
| A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations. Lung cancer (Amsterdam, Netherlands) 2023 8 184 107349. Takashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, Shoichi Kuyama, Koji Inoue, Toshihide Yokoyama, Nobuhiro Kanaji, Masayuki Yasugi, Takuo Shibayama, Keisuke Aoe, Nobuaki Ochi, Kazunori Fujitaka, Masahiro Kodani, Yutaka Ueda, Kazuhiko Watanabe, Akihiro Bessho, Keisuke Sugimoto, Isao Oze, Katsuyuki Hotta, Katsuyuki Kiu |
| How to Treat EGFR-Mutated Non-Small Cell Lung Cancer. JACC. CardioOncology 2023 8 5 (4): 542-545. Neel Belani, Katherine Liang, Michael Fradley, Julia Judd, Hossein Borgha |
| Low?dose anlotinib combined with EGFR?TKI can be used as an alternative for EGFR?TKI?resistant non?small cell lung cancer in elderly patients. Oncology letters 2023 7 26 (2): 323. Yi Chen, Nanyuan Jiang, Xiao Liang, Nan Chen, Yun Chen, Chen Zhang, Junfeng Shi, Renhua G |
| Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted oncology 2023 6 . Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, Gee-Chen Chang, Wu-Chou Su, Te-Chun Hsia, Jian Su, Anne Kuei-Fang Wang, Min-Hua Jen, Tarun Puri, Jin-Yuan Sh |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
| Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations. Thoracic cancer 2023 4 . Zhang Ling, You Yunhong, Liu Xueli, Liu Fengjuan, Nie Keke, Ji Youx |
| A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. Journal of cancer research and clinical oncology 2023 4 . Sa Huanlan, Shi Yan, Ding Chunxia, Ma Kew |
| Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung cancer (Amsterdam, Netherlands) 2023 3 178 151-156. Lv Chao, Fang Wentao, Wu Nan, Jiao Wenjie, Xu Shidong, Ma Haitao, Wang Jia, Wang Rui, Ji Chunyu, Li Shaolei, Wang Yuzhao, Yan Shi, Lu Fangliang, Pei Yuquan, Liu Yinan, Yang Y |
| Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC cancer 2023 1 23 (1): 6. Miura Satoru, Koh Yasuhiro, Azuma Koichi, Yoshioka Hiroshige, Koyama Kenichi, Teraoka Shunsuke, Ishii Hidenobu, Kibata Kayoko, Ozawa Yuichi, Tokito Takaaki, Oyanagi Jun, Shimokawa Toshio, Kurata Takayasu, Yamamoto Nobuyuki, Tanaka Hiros |
| Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight. Cancer science 2023 1 . Fujiwara Yutaka, Makihara Reiko, Hase Tetsunari, Hashimoto Naozumi, Naito Tomoyuki, Tsubata Yukari, Okuno Takae, Takahashi Toshiaki, Kobayashi Haruki, Shinno Yuki, Zenke Yoshitaka, Ikeda Takaya, Hosomi Yukio, Watanabe Kageaki, Kitazono Satoru, Sakiyama Naomi, Makino Yoshinori, Yamamoto Nobo |
| Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncology letters 2023 1 25 (2): 62. Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim |
| Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 2023 1 . Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kasai Hidefumi, Kuniyoshi Ouki, Kimura Motonori, Hakamata Jun, Nakada Hideo, Suehiro Naoya, Nakaya Naoki, Nakajima Hideo, Ikemura Shinnosuke, Kawada Ichiro, Yasuda Hiroyuki, Terai Hideki, Jibiki Aya, Kawazoe Hitoshi, Soejima Kenzo, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomono |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: